Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Abstract

Successfully treating hepatitis C virus with DAAs in patients without clinically apparent advanced liver disease translates into a significant mortality benefit. (Hepatology 2018).